ड्यूटास्टेराइड और टैम्सुलोसिन और सिल्डेनाफिल का इंटरैक्शन

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives.

Hypotension when Co-administered with Alpha-blockers or Antihypertensives Alpha-blockers Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers.

Consider the following: Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor.

Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors.

In patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest dose [see Dosage and Administration ( 2.2 ) ] .

Exercise caution with concomitant use of phosphodiesterase-5 (PDE-5) inhibitors, as this may increase the risk of hypotension.

Phosphodiesterase-5 (PDE-5) Inhibitors Caution is advised when alpha-adrenergic–antagonist-containing products, including JALYN, are coadministered with PDE-5 inhibitors.

Alpha-adrenergic antagonists and PDE-5 inhibitors are both vasodilators that can lower blood pressure.